Stroke

Experts discuss the evolving philosophy of stroke care, highlighting the importance of rapid recognition, advanced imaging, and expanding treatment pathways for patients with suspected stroke. [WATCH TIME: 4 minutes]

Experts discuss how updated stroke guidelines introduce new considerations for pediatric stroke care, emphasizing improved recognition, specialized expertise, and collaboration between pediatric and adult stroke centers. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 13, 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The neurologist at LMU Munich University Hospital discussed newly published data supporting plasma brain-derived tau as a dynamic biomarker of infarct growth and treatment response in acute ischemic stroke. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Andrei Alexandrov, MD, an award-winning leader in stroke research and clinical care, discussed the clinical impact of the latest stroke guidelines and their implications for diagnosis and care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

Anjail Sharrief, MD, Director of Stroke Prevention for the Institute of Stroke and Cerebrovascular Disease at UTHealth Houston, reflects on Black History Month, structural drivers of stroke inequities, and building systems that advance equitable brain health.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lauren Sansing, MD, MS, FAHA, FANA. [LISTEN TIME: 27 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Phase 2 trials suggest LT3001 is safe in acute ischemic stroke and may boost day-90 recovery, paving the way for a global Phase 3.

Leaders from Brainomix provided commentary on data from ISC 2026, discussing how automated net water uptake from routine CT imaging may refine stroke severity assessment, thrombectomy selection, and system-level treatment equity.

High-dose constraint-induced therapy boosts arm function in toddlers after perinatal stroke, with gains lasting 6 months in phase 3 trial.

Andrew Russman, DO, director of Cleveland Clinic’s Comprehensive Stroke Center, provided an analysis of the phase 3 OCEANIC-STROKE data of asundexian in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack.

A professor of neurology from the University of Barcelona discussed the clinical implications of adding intra-arterial alteplase after thrombectomy in patients with Large-vessel occlusion (LVO) acute ischemic stroke at ISC 2026.

An interim DSMB review halted the rivaroxaban arm of the NIH-funded CAPTIVA trial in symptomatic intracranial atherosclerotic stroke due to increased safety events and futility compared with standard dual antiplatelet therapy.